Editorial
Molecular targeted therapies in non-small cell lung cancer: where we are
Abstract
In the last twenty years the landscape of treatment for advanced non-small cell lung cancer (NSCLC) has been totally revolutionized by the identification of somatic genetic alterations of DNA, specific for type of tumor, which are the molecular driving events for oncogenesis and, at the same time, very sensitive targets for individualized treatments.
